Anebulo Pharmaceuticals (ANEB) Other Non Operating Income (2021 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Other Non Operating Income of -$34.0 for Q4 2025, down 172.34% year-over-year from $47.0 in Q4 2024, and up 64.58% quarter-over-quarter from -$96.0 in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Other Non Operating Income (2021 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Other Non Operating Income for 5 consecutive years, with -$34.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non Operating Income fell 172.34% year-over-year to -$34.0; the TTM figure through Dec 2025 stood at -$1089.0 (down 155.53% YoY), while the FY2025 annual figure was -$1195.0, down 112.9% from the prior year.
- Other Non Operating Income advanced to -$34.0 in Q4 2025 per ANEB's latest filing, from -$96.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $7657.0 in Q3 2023 and bottomed at -$22646.0 in Q4 2022.
- Historically, Other Non Operating Income has averaged -$1721.1 across 5 years, with a median of -$247.5 in 2022.
- Annual changes were most pronounced in 2022 — Other Non Operating Income sank 1111.66% — and 2023, when it surged 3711.79%.
- Anebulo Pharmaceuticals' Other Non Operating Income stood at -$1869.0 in 2021, then tumbled by 1111.66% to -$22646.0 in 2022, then soared by 97.38% to -$594.0 in 2023, then jumped by 107.91% to $47.0 in 2024, then slumped by 172.34% to -$34.0 in 2025.
- Business Quant data shows ANEB's Other Non Operating Income at -$34.0 in Q4 2025, -$96.0 in Q3 2025, and -$431.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -34.00 |
| Sep 30, 2025 | -96.00 |
| Jun 30, 2025 | -431.00 |
| Mar 31, 2025 | -528.00 |
| Dec 31, 2024 | 47.00 |
| Sep 30, 2024 | -283.00 |
| Jun 30, 2024 | -124.00 |
| Mar 31, 2024 | 2,321.00 |
| Dec 31, 2023 | -594.00 |
| Sep 30, 2023 | 7,657.00 |
| Jun 30, 2023 | -1,197.00 |
| Mar 31, 2023 | -13,082.00 |
| Dec 31, 2022 | -22,646.00 |
| Sep 30, 2022 | -212.00 |
| Jun 30, 2022 | -4,590.00 |
| Mar 31, 2022 | 3,153.00 |
| Dec 31, 2021 | -1,869.00 |
| Sep 30, 2021 | 1,529.00 |